Indeed, most Hodgkin's lymphomas express decreased or negative MHC class I molecules but show upregulated PD-L1 expression, yet patients responded well to immunotherapy blockading PD-1/PD-L1, indicating the pivotal role of the anti-tumor efficacy of NK cells (70, 72). This evidence concerns the gene PDCD1 and neoplasm.